- Home
- KNSA vs DYN Comparison
KNSA vs DYN Comparison
Compare KNSA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | DYN |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNSA | DYN |
|---|---|---|
| Price | $47.48 | $14.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | ★ $53.71 | $39.94 |
| AVG Volume (30 Days) | 445.1K | ★ 1.8M |
| Earning Date | 04-03-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.68 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $423,239,000.00 | N/A |
| Revenue This Year | $62.99 | N/A |
| Revenue Next Year | $33.30 | N/A |
| P/E Ratio | $82.68 | ★ N/A |
| Revenue Growth | ★ 56.60 | N/A |
| 52 Week Low | $18.26 | $7.01 |
| 52 Week High | $47.51 | $25.00 |
Technical Indicators
Market Signals| Indicator | KNSA | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 31.28 |
| Support Level | $43.55 | $14.67 |
| Resistance Level | $47.51 | $15.60 |
| Average True Range (ATR) | 1.67 | 0.99 |
| MACD | 0.26 | -0.21 |
| Stochastic Oscillator | 95.93 | 4.66 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.